MAGE-A4 peptide dual T cell engagers
US12161673B2 · kind B2 · utility
0Cited by
12References
40Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 13, 2023 |
| Grant date | Dec 10, 2024 |
| Priority date | — |
| Expiry date | Sep 13, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein are antigen binding proteins with specificity to Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC). Also described are multispecific antigen binding proteins comprising an antigen binding domain with specificity to CD3, and at least one MAGE-A4 pMHC antigen binding domain. Methods of treating cancer with the same are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.